Concurrent Bupropion / Varenicline for Smoking Cessation

Last updated: August 4, 2014
Sponsor: Duke University
Overall Status: Completed

Phase

3

Condition

Tobacco Use Disorder

Stimulant Use Disorder

Treatment

N/A

Clinical Study ID

NCT01303861
Pro00027351
1P50DA027840-01A1
  • Ages 18-65
  • All Genders

Study Summary

This study focuses on the first step in developing an algorithm for maximizing quit-smoking success based on an adaptive approach, which changes treatment from the initial nicotine replacement therapy (NRT) when that treatment alone may not be sufficient. These NRT "non-responders" are switched (in double-blind fashion) before the quit date to receive either varenicline alone or varenicline paired with bupropion. Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-65 years old;

  • smoked an average of at least 10 cigarettes per day for three cumulative years;

  • have an expired air CO reading assessed at screening of at least 10ppm;

  • express a desire to quit smoking within the next 30 days.

Exclusion

Exclusion Criteria:

  • Hypertension (systolic >140 mm Hg, diastolic >100 mm Hg, coupled with a history ofhypertension); subjects with no previous diagnosis of hypertension may have ascreening blood pressure up to 160/100.

  • Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg).

  • Coronary heart disease;

  • Lifetime history of heart attack;

  • Cardiac rhythm disorder (irregular heart rhythm);

  • Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);

  • Cardiac (heart) disorder (including but not limited to valvular heart disease, heartmurmur, heart failure);

  • History of skin allergy;

  • Active skin disorder (e.g., psoriasis) within the last five years, except minor skinconditions (including but not limited to facial acne, minor localized infections, andsuperficial minor wounds);

  • Liver or kidney disorder (except kidney stones, gallstones);

  • Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;

  • Active ulcers in the past 30 days;

  • Currently symptomatic lung disorder/disease (including but not limited to chronicobstructive pulmonary disease (COPD), emphysema, and asthma);

  • Brain abnormality (including but not limited to stroke, brain tumor, and seizuredisorder);

  • Migraine headaches that occur more frequently than once per week;

  • Recent, unexplained fainting spells;

  • Problems giving blood samples;

  • Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is lessthan 180mg/dcl and HbA1c is less than 7%);

  • Current cancer or treatment for cancer in the past six months (except basal orsquamous cell skin cancer);

  • Other major medical condition;

  • Current psychiatric disease (with the exception of anxiety disorders, obsessivecompulsive disorder (OCD) and ADHD);

  • Suicidal ideation (within the past 10 years) or lifetime occurrence of attemptedsuicide;

  • Current depression;

  • Bulimia or anorexia;

  • Pregnant or nursing mothers;

  • Alcohol abuse;

  • Use of Opiate medications for pain or sleep in the past 14 days;

  • Significant adverse reaction to nicotine patches, nicotine inhalers, bupropion /Wellbutrin / Zyban or Chantix / Varenicline in the past.

  • Use (within the past 30 days) of:

  • Illegal drugs (or if the urine drug screen is positive),

  • Experimental (investigational) drugs;

  • Psychiatric medications including antidepressants, anti-psychotics or any othermedications that are known to affect smoking cessation (e.g. clonidine);

  • Smokeless tobacco (chewing tobacco, snuff), cigars, pipes or e-cigarettes;

  • Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any othersmoking cessation aid.

Study Design

Total Participants: 702
Study Start date:
March 01, 2011
Estimated Completion Date:
July 31, 2013

Connect with a study center

  • Duke Center for Nicotine and Smoking Cessation Research

    Charlotte, North Carolina 28210
    United States

    Site Not Available

  • Duke Center for Nicotine and Smoking Cessation Research

    Durham, North Carolina 27705
    United States

    Site Not Available

  • Duke Center for Nicotine and Smoking Cessation Research

    Raleigh, North Carolina 27609
    United States

    Site Not Available

  • Duke Center for Nicotine and Smoking Cessation Research

    Winston-Salem, North Carolina 27103
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.